Spartalizumab

Tax included
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-1 with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC).
MedChemExpress 
HY-P9972

Data sheet

Size
Multiple sizes
Reactivity
PD-1/PD-L1
Application
Cancer-programmed cell death
CAS
1935694-88-4